Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PACHA-02: Postoperative Hepatic Arterial Chemotherapy After Resection of Colorectal Liver Metastases
NCT07284394Phase 3Not yet recruiting
- Sponsor
- Unicancer
- Start
- Jul 2026
- Primary completion
- Jan 2031
- Modality
- DNA Intercalators/Alkylators
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin in colorectal cancer (CRC) and liver metastasis (2 arms), sponsored by Unicancer. Primary endpoint: Recurrence-free survival up to 8.5 years. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
oxaliplatin
03
Conditions
colorectal cancer (CRC)liver metastasis
Beyond the preview
Go deeper on NCT07284394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07284394.